🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06041282
Recruiting Not applicable

Conservative Treatment of Early Adhesive Capsulitis

NCT06041282 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Started
2026-01-01
Last updated
2026-01-02

Condition(s) studied

Adhesive Capsulitis

Investigational drug(s) / intervention(s)

manipulation under anesthesiasupervised home rehabilitation

manipulation under anesthesia: After the anesthesia took effect, the patient was placed in the supine position, and the experienced surgeon stood at the head of the bed to release the affected limb by four angles of forward flexion, abduction, external rotation and internal rotation. After the operation is completed, 1ml de Bosson (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) is injected once.

supervised home rehabilitation: The doctor instructs the patient in exercise training at the outpatient clinic. At each clinic visit, the doctor will guide the different stages of the movement. At the first visit, the doctor guides the patient through the first phase of the rehabilitation program to improve the patient's basic mobility. At the first month of follow-up, the second phase of rehabilitation program was guided, and the recovery of mobility was accompanied by muscle training, including wall climbing and muscle resistance exercises. 1ml Debossone (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) was injected once at the clinic. All the training required patients to do their best at home to complete 3 sets of 5 each. At the end of each day, the patient will upload a video to the platform, and the doctor will evaluate whether the patient's recovery is in place.

Study summary

A prospective, multicentre, randomized controlled study comparing the efficacy of conservative treatment for early adhesive capsulitis

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients in our hospital who need manual release of periarthritis of shoulder or home rehabilitation treatment; * Unilateral and primary periarthritis of shoulder * Age ≥40 years old and ≤80 years old, regardless of gender. * Forward flexion movement is more than 50% limited compared with the contralateral. * Duration of disease ≤3 months Exclusion Criteria: * Patients with a previous history of shoulder joint surgery * Patients who did not complete the follow-up within the specified time * Patients with other shoulder diseases. * Patient with systemic immune disease. * Patients who have participated in clinical trials or are conducting other clinical trials within 3 months before screening * Patients with serious primary cardiovascular diseases, lung diseases, endocrine and metabolic diseases, or serious diseases affecting their survival, such as tumor or AIDS, are considered not suitable for admission. * Patients with serious liver diseases, kidney diseases, hematological diseases, such as kidney function (BUN, Cr) more than the upper limit of normal, liver function (ALT, AST, TBIL) more than 2 times the upper limit of normal. * Patients with viral hepatitis, infectious diseases, abnormal blood coagulation mechanism and other diseases that researchers consider inappropriate for surgery. * Pregnant or lactating women, or those planning to get pregnant during the test, with positive urine HCG test results before the test; Menstruating women should wait until their period is over before undergoing surgery. * Patients with severe neurological and mental diseases. * Suspected or true history of alcohol and drug abuse.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
2nd Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06041282 on ClinicalTrials.gov ↗ ← All trials in China